<DOC>
	<DOCNO>NCT02213705</DOCNO>
	<brief_summary>The main ailm phase I-II study evaluate toxicity efficacy allogenic mesenchymal stem cell therapy treat severe systemic sclerosis . In practice treatment give patient rapidly evolutive disease refractory cyclophosphamide .</brief_summary>
	<brief_title>Treatment Refractory Sever Systemic Scleroderma Injection Allogeneic Mesenchymal Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<criteria>Age &gt; 18 year &lt; 70 year . Established diagnosis systemic sclerosis accord criterion American College Rheumatology SSc poor prognosis , involve lifethreatening sever visceral impairment ( cardiac , pulmonary renal ) AND `` ) contraindicating use b ) resistant `` immunosuppressive therapy conventionally use severe form disease accord European recommendation EUSTAR ( www.eustar.org ) EBMT ( www.ebmt.org ) rely high dos iv cyclophosphamide ( either monthly bolus least six month intensification autograft Hematopoietic Stem Cells ) SSc fibrosing lung damage threaten vital prognosis excludes lung transplant . These form severe serious SSc WITH least 6 month followup completion prior immunosuppressive therapy high dos iv cyclophosphamide make , combine vary degree : rapidly progressive skin lesion score Rodnan &gt; 15 one major visceral lesion define follow : 1 . Respiratory disease : DLCO &lt; 60 % FVC â‰¤70 % theoretical value presence interstitial lung disease ( abnormalities chest radiograph / lung HRCT thin section ) . It necessary ensure nonrelated etiology scleroderma eliminate ; example : obstructive lung disease ( chronic obstructive pulmonary disease pulmonary emphysema ) . If fibrosing lung disease threaten vital prognosis , ensure exclusion possible lung transplant . And/or 2 . Heart disease : congestive heart failure reversible , ventricular atrial rhythm disturbance define recurrent episode atrial fibrillation atrial flutter , recurrent paroxysmal atrial tachycardia ventricular tachycardia , atrioventricular block second third degree , pericardial effusion high abundance need specific treatment medical type ( introduction steroid ) surgical type ( drainage ) . It necessary ensure nonrelated etiology scleroderma remove . Signed informed consent . Presence consent intrafamilial MSC donor Affiliation social security . Pregnancy absence appropriate contraception throughout study . Respiratory Disease : systolic Pulmonary arterial pressure ( PASP ) &gt; 55mmHg ( echocardiography right heart catheterization ) ; DLCO &lt; 30 % theorical ; Respiratory failure define oxygen arterial pressure rest ( PaO2 ) &lt; 8 kPa ( &lt; 60 mmHg ) / blood pressure carbon dioxide rest ( PaCO2 ) &gt; 6.7 kPa ( &gt; 50 mmHg ) without oxygen therapy . Renal Disease : Calculated creatinine clearance &lt; 20 ml/mn/m2 Sequelae cystopathy post treatment cyclophosphamide Heart disease : Clinical sign congestive heart failure refractory ; Left ventricular ejection fraction &lt; 35 % myocardial scintigraphy echocardiography ; Pulmonary arterial hypertension confirm right catheterization suspect pulmonary hypertension systolic PAP echography &gt; 40 mmHg Chronic atrial fibrillation require oral anticoagulant therapy ; Uncontrolled ventricular arrhythmia ; Pericardial effusion hemodynamic compromise assess echocardiography . Hepatic Disease : Hepatic impairment define persistent increase transaminases bilirubin 3 time normal . Psychiatric disorder , include drug take alcohol abuse . Active neoplasia concomitant myelodysplasia , antecedent neoplasia . Bone marrow failure define neutropenia &lt; 0.5 x 109 / L , thrombocytopenia &lt; 50 x 109 / L , anemia &lt; 8 g / dL , CD4 lymphopenia &lt; 200 x 106 / L. Uncontrolled systemic hypertension . Uncontrolled acute chronic infection , HIV1 , 2 HTLV1 , 2seropositivity . Chronic hepatitis B C active . Significant exposure bleomycin , toxic oil , vinyl chloride , trichloroethylene silica ; eosinophiliamyalgia syndrome , eosinophilia fasciitis . Risk poor patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>SYSTEMIC SCLERODERMA</keyword>
	<keyword>TRANSPLANTATION</keyword>
	<keyword>ALLOGENEIC MESENCHYMAL STEM CELLS</keyword>
	<keyword>ADULT</keyword>
</DOC>